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Edited by Lukas HuberAbstract Ectopic expression of oncogenic H-Ras in cells results
in increases of cell susceptibility to the anticancer agent
FR901228. Investigating the roles of Ras-induced pathways in
FR901228-induced apoptosis, we have found that the phosphati-
dylinositol 3-kinase pathway plays an anti-apoptotic role,
whereas the stress-activated protein kinase p38 pathway plays
a pro-apoptotic role in FR901228-induced apoptosis. Interest-
ingly, the extracellular signal-regulated kinase (ERK) pathway
plays an anti-apoptotic role in non-transformed cells; however,
it plays a pro-apoptotic role in Ras-transformed cells in response
to FR901228 treatment. An essential role of the ERK pathway in
regulating caspase-3 contents may contribute to its pro-apoptotic
role in Ras-transformed cells.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Induction of oncogenic Ras proteins leads to cellular trans-
formation and promotes tumorigenesis [1–4]. We used stably
H-ras-transformed 10T1/2 cell lines as target cells and revealed
a discriminating agent, FR901228, that induced selective apop-
tosis of the fully Ras-transformed cells, but it induced growth
arrest of non-transformed counterpart cells in the G0/G1
phase of the cell cycle [5]. FR901228 is a bi-cyclic depsipeptide
isolated from Chromobacterium violaceum cultures, possesses
potent antitumor eﬀects for murine and human tumor cells,
and exhibits histone deacetylase inhibitor activity [6–8]. To
understand Ras-potentiated signaling events leading to the in-
creased cell susceptibility to FR901228, we have recently used
a tetracycline-inducible expression cell system, 10T1/2-TR-H-
ras [9], to investigate signaling pathways which are aberrantly
regulated in the course of Ras-induced cellular transformation.
We have reported that procaspase-3 protein content is highlyAbbreviations: ERK, extracellular signal-regulated kinase; PI3-K, ph-
osphatidylinositol 3-kinase; SAPK/p38, stress-activated protein kinase
p38; PARP, poly(ADP-ribose) polymerase
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and the extracellular signal-regulated kinase (ERK) is essential
for the expression of procaspase-3 [10]. The elevated procas-
pase-3 protein content appears to play a role in facilitating
the proteolytic production of active caspase-3 during the
induction of selective apoptosis of Ras-transformed cells by
FR901228 [10]. However, the roles of Ras-activated signaling
pathways, including the ERK and caspase-3 pathways as well
as the phosphatidylinositol 3-kinase (PI3-K) [11], and stress-
activated protein kinase p38 (SAPK/p38) [12–15] pathways
in the Ras-increased cell susceptibility to FR901228 remain
to be clariﬁed.
In this communication, we revealed the roles of PI3-K,
SAPK/p38, ERK, and caspase-3 pathways in the selective
FR901228-induced apoptosis of cells undergoing Ras-induced
cellular transformation.2. Materials and methods
2.1. Cell culture and reagents
The 10T1/2-TR-H-ras cell line, in which ectopic expression of H-Ras
is controlled by addition of tetracycline into cultures [9], was derived
from mouse embryo ﬁbroblast 10T1/2 cells with a tetracycline-induc-
ible T-RExe expression system (Invitrogen, Carlsbad, CA). Cells were
routinely maintained in Basal Medium Eagle (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine serum, 100
U/ml penicillin and 100 lg/ml streptomycin, and incubated at 37 C
[9]. Stock aqueous solutions of FR901228 (Chemistry and Synthesis
Branch, The National Cancer Institute, Bethesda, MD), LY294002,
SB203580, Ac-Asp-Glu-Val-Asp-CHO (Alexis, San Diego, CA) and
U0126 (Cell Signaling Technology, Beverly, MA) were prepared in di-
methyl sulfoxide and were diluted in culture medium before treatment
of cultured cells.
2.2. Flow cytometric analysis of cell population
Cells were trypsinized from cultures and rinsed with Ca2+ and Mg2+
free phosphate-buﬀered saline, ﬁxed in ethanol, and stained with pro-
pidium iodide [5]. Flow cytometry analysis was performed on the
Coulter EPICS Elite Cytometer (Hialeah, FL) using 15 mW air-cooled
argon laser to produce 488 nm light. PI ﬂuorescent light emission was
collected with a 610LPDC ﬁlter. Extended analysis of DNA content
and calculation of the percentage of cells in each phase of the cell cycle
were performed on Multicycle software (Phoenix Flow System, San
Diego, CA).2.3. Western immunoblotting
Cells were lysed in a buﬀer (10 mM Tris–HCl, 150 mM NaCl, 1%
Triton X-100, 5 mM EDTA, 10 mM sodium pyrophosphate, 10%
glycerol, 0.1% Na3VO4 and 50 mM NaF, pH 7.4) [5]. Cell lysates wereblished by Elsevier B.V. All rights reserved.
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20000 · g for 20 min. Protein concentration in cell lysates was mea-
sured using the BCA assay (Pierce, Rockford, IL). Equal amounts of
cellular proteins were resolved by electrophoresis in either 10 or 14%
sodium dodecyl sulfate–polyacrylamide gels and transferred to nitro-
cellulose ﬁlters for Western immunoblotting as previously described
[5]. Speciﬁc antibodies to Akt, SAPK/p38 and poly(ADP-ribose) poly-
merase (PARP), and speciﬁc antibodies to phosphorylated/activated
forms of Akt, p38 and Erk1/2 were purchased from Cell Signaling
Technology. Speciﬁc antibodies to H-Ras, Erk1/2, phosphorylated
Hsp27 and Hsp27 protein were purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA). Antigen–antibody complexes on ﬁlters were
detected by the Supersignal chemiluminescence kit as indicated by the
manufacturer (Pierce) and visualized by autoradiography.
2.4. Cell death assay
Quantiﬁcation of cell death in cultures was determined using a Cell
Death Detection ELISA kit (Roche Diagnostics, Indianapolis, IN). As
described by the manufacturer, cell lysates were incubated with
anti-histone antibodies. Fragmented DNAs in the complexes of nucle-
osomes with histone were detected with peroxidase-conjugated
anti-DNA antibody and stained with peroxidase substrate 2,2 0-azino-
bis-(3-ethylbenzthiazoline-6-sulfonic acid). Quantiﬁcation of the extent
of cell death was determined with an ELISA reader. Statistical signif-
icance was analyzed by Students t test (2-tailed).Fig. 1. Cell growth arrest, apoptosis, and signaling pathways induced
by H-Ras and FR901228. Cultures of 10T1/2-TR-H-ras cells were
treated with 100 ng/ml tetracycline (Tet) to induce ectopic expression
of H-Ras and cellular transformation for 48 h in the absence () and
presence (FR) of 1 nM FR901228. (A) Cell populations were analyzed
by ﬂow cytometry to detect apoptotic cells in the entire cell population
and living cells in each phase of the cell cycle. Thin lines show data
detected by ﬂow cytometer. Thick lines and ﬁlled peaks show data
analyzed by modeling Multicycle software. (B-1, B-2, B-3 and B-4) Cell
lysates were analyzed by Western immunoblotting with speciﬁc
antibodies to detect levels of ectopically expressed H-Ras (B-1),
phosphorylated/activated Akt (p-Akt) and Akt protein (B-2), phos-
phorylated/activated p38 (p-p38) and p38 protein (B-3), and phos-
phorylated/activated Erk1/2 (p-Erk1/2) and Erk1/2 protein (B-4).3. Results and discussion
3.1. Cell growth arrest, apoptosis and signaling pathways
induced by H-Ras and FR901228
To conﬁrm the diﬀerential activities of FR901228 for cells
undergoing Ras-induced cellular transformation and non-
transformed counterpart cells, cultures of 10T1/2-TR-H-ras
cells were treated with tetracycline to induce ectopic expression
of oncogenic H-Ras in the presence and absence of FR901228
at a discriminating concentration of 1 nM for 48 h. As shown
in Fig. 1A, FR901228 treatment of non-transformed cells
(/FR) elicited only a modest population of apoptotic
cells (Apo: 8%) and growth arrest of the major population of
cells in the G0/G1 phase of the cell cycle (G0/G1: 88%), as
compared to untreated counterpart cultures (/). In contrast,
a substantial population of apoptotic cells (Apo: 33%) was
detected in FR901228-treated cultures which were undergoing
Ras-induced cellular transformation (Tet/FR), as compared to
cultures undergoing cellular transformation in the absence of
FR901228 (Tet/). The major population of surviving cells
in the FR901228-treated Ras-transformed cultures (Tet/FR)
was also growth-arrested in G0/G1 phase of the cell cycle
(G0/G1: 86%). As shown in Fig. 1B-1, induction of ectopically
expressed H-Ras was veriﬁed in tetracycline-treated cultures
by Western immunoblotting (lanes 3 and 4). These results val-
idate the discriminating activity of FR901228 to preferably in-
duce apoptosis of cells undergoing Ras-induced cellular
transformation.
Analysis of the eﬀects of FR901228 on the PI3-K (Fig. 1B-2),
SAPK/p38 (Fig. 1B-3) and ERK (Fig. 1B-4) pathways
showed that the FR901228 treatment resulted in activation
of these pathways in non-transformed cells (lane 2) and re-
sulted in modest enhancement of these pathways in cells
undergoing Ras-induced cellular transformation (lane 4), as
determined by the increased phosphorylation of Akt (p-
Akt), p38 (p-p38) and Erk1/2 (p-Erk1/2), respectively. Consis-
tent with our previous results using stably Ras-transformed
cells [5], protein levels of Akt were reduced in FR901228-trea-
ted non-transformed (Fig. 1B-2, lane 2) and Ras-transformed(lane 4) cultures. Reduction of Akt protein was correlated
with the induction of apoptosis (Fig. 1A) by FR901228.
However, the PI3-K pathway appeared to be enhanced to in-
crease the speciﬁc phosphorylation of Akt in order to achieve
either an elevated or a comparable, overall level of phosphor-
ylated Akt in either non-transformed or Ras-transformed
cells for cell survival in response to the FR901228 treatment.
Protein levels of p38 (Fig. 1B-3) and Erk1/2 (Fig. 1B-4) were
not changed in either non-transformed (lane 2) or Ras-trans-
formed (lane 4) cells after being treated with FR901228, but
their protein phosphorylation was either induced in non-
transformed cultures or slightly enhanced in Ras-transformed
cultures by the FR901228 treatment. In addition, activation
of another SAPK pathway mediated through JNK was not
detectably involved in the cells undergoing either Ras-induced
cellular transformation or FR901228 treatment (data not
shown).
3.2. FR901228-induced cell death modulated by the PI3-K,
SAPK/p38 and ERK pathways
To investigate the roles of the PI3-K, SAPK/p38 and
ERK pathways in the selective apoptosis of Ras-transformed
Fig. 2. FR901228-induced cell death modulated by the PI3-K, SAPK/
p38 and ERK pathways. Cultures of 10T1/2-TR-H-ras cells () were
treated with 100 ng/ml tetracycline (Tet) to induce ectopic expression
of H-Ras in the absence () and presence (+) of 1 nM FR901228 (FR).
Cells were also simultaneously treated with 1 lM LY294002 (LY), 1
lM SB203580 (SB) or 20 lMU0126 (U0) for 48 h to speciﬁcally block
the PI3-K, SAPK/p38 or ERK pathway, respectively. Cell lysates were
analyzed by Western immunoblotting using speciﬁc antibodies to
detect levels of phosphorylated/activated Akt (p-Akt) and Akt protein
(A-1), phosphorylated heat shock protein 27 (p-Hsp27) and Hsp27
protein (B-1), and phosphorylated/activated Erk1/2 (p-Erk1/2) and
Erk1/2 protein (C-1). (A-2, B-2 and C-2) Quantiﬁcation of cell death in
these cultures was determined. Relative cell death was normalized by
the value determined in untreated cells which was set as 1. Each value
represents a mean of triplicates and error bars represent standard
deviation. Statistical signiﬁcance was analyzed by Students t test. a
indicates that P < 0.001 versus FR (column 2). b indicates that
P < 0.05 versus FR/Tet (column 6). c indicates that P < 0.01 versus FR
(column 2). d indicates that P < 0.05 versus FR/Tet (column 6). e
indicates that P < 0.01 versus FR (column 2). f indicates that P < 0.05
versus FR/Tet (column 6).
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blocking these pathways on the FR901228-induced apoptosis.
We used LY294002, SB203580 and U0126 to speciﬁcally
block the PI3-K, SAPK/p38 and ERK pathways, respec-
tively. LY294002 speciﬁcally suppresses PI3-K activity [16],
SB203580 speciﬁcally suppresses p38 activity [17], and
U0126 speciﬁcally suppresses Mek1 and Mek2 [18,19]. Suc-
cessful inhibition of PI3-K by 1 lM LY294002 was deter-
mined by the suppressed phosphorylation of its downstream
substrate Akt (p-Akt) (Fig. 2A-1) in both non-transformed
cultures (lanes 3 and 4) and cultures undergoing Ras-induced
cellular transformation (lanes 7 and 8). Inhibition of the
SAPK/p38 pathway by SB203580 at 1 lM was determined
by the suppressed phosphorylation of its downstream sub-
strate heat shock protein Hsp27 (p-Hsp27) [20] (Fig. 2B-1,
lanes 3, 4, 7 and 8). Successful blockage of the ERK pathway
by 20 lM U0126 was determined by the suppressed phos-
phorylation of Erk1/2 (p-Erk1/2) (Fig. 2C-1, lanes 3, 4, 7
and 8). To detect the eﬀect of these pathway inhibitors on
FR901228-induced cell death, a sensitive method with Cell
Death Detection ELISA kit was used to semi-quantitatively
measure the extents of apoptosis in cultures. As shown in
Fig. 2A-2, B-2 and C-2, a modest extent of cell death was de-
tected in cultures of non-transformed cells treated with
FR901228 (column 2) as compared to the untreated growing
cultures (column 1). The extents of cell death were pro-
foundly increased in cultures undergoing Ras-induced cellular
transformation by FR901228 treatment (column 6) as com-
pared to the untreated transformed cultures (column 5).
The results were consistent with the results of ﬂow cytometric
analysis of cell death in FR901228-treated cultures (Fig. 1A).
The extents of apoptotic cells were not changed in either non-
transformed (column 3) or Ras-transformed (column 7) cul-
tures by the treatment with LY294002 (Fig. 2A-2),
SB203580 (Fig. 2B-2) or U0126 (Fig. 2C-2) alone. However,
treatment of either non-transformed cultures (Fig. 2A-2, col-
umn 4) or cultures undergoing Ras-induced cellular transfor-
mation (column 8) with LY294002 resulted in increasing
FR901228-induced cell death. The results indicate that the
PI3-K pathway played an anti-apoptotic role in modulating
cell survival of both non-transformed and Ras-transformed
cells in response to FR901228 treatment. In contrast, treat-
ment of either non-transformed cultures (Fig. 2B-2, column
4) or cultures undergoing Ras-induced cellular transforma-
tion (column 8) with SB203580 resulted in reducing
FR901228-induced cell death. These results indicated that
the SAPK/p38 pathway plays a pro-apoptotic role in modu-
lating cell death of both non-transformed and Ras-trans-
formed cells in response to FR901228 treatment.
Interestingly, as shown in Fig. 2C-2, treatment of non-trans-
formed cultures with FR901228 in the presence of U0126 re-
sulted in increased extents of cell death (column 4); however,
the highly FR901228-induced cell death in cultures undergo-
ing Ras-induced cellular transformation was reduced by the
U0126 blockage of the ERK pathway (column 8). The
ERK pathway appears to play an anti-apoptotic role in
non-transformed cells, but it plays a pro-apoptotic role in
cells undergoing Ras-induced cellular transformation to mod-
ulate cell susceptibility to the FR901228 treatment. In addi-
tion to the broadly recognized anti-apoptotic role of the
ERK pathway for cell survivability [2], the ERK pathway
has been reportedly involved in the process of apoptosis in-duced by Ras [21], anchorage deprivation [22], oxidative
stress [23], cisplatin [24] and PKC [25]. However, the mecha-
nism for the ERK pathway to mediate the pro-apoptotic sig-
nals is far from clear.
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pathway
Wehave reported that procaspase-3 content is highly elevated
in mouse embryo ﬁbroblasts transformed by oncogenic H-Ras,
and the ERK pathway plays an essential role in regulating gene
expression of procaspase-3 [10]. However, the role of caspase-3
in the FR901228-induced cell death needs to be clariﬁed. To
investigate if caspase-3 is involved in FR901228-induced cell
death, cultures were pre-treated with a potent caspase-3 inhibi-
tor, Ac-Asp-Glu-Val-Asp-CHO [26], followed by the induction
of ectopically expressed H-Ras with tetracycline in the presence
of FR901228. As shown in Fig. 3A, inhibition of caspase-3
activity was determined by the reduced production of proteo-
lytic PARP, which is a caspase-3 substrate [27]. Pre-treatment
with Ac-Asp-Glu-Val-Asp-CHO alone did not cause any
detectable changes in either production of proteolytic PARP
(Fig. 3A) or cell death (Fig. 3B) in either non-transformed cul-
tures (lane and column 3) or cultures undergoing Ras-induced
cellular transformation (lane and column 7). The FR901228
treatment induced proteolytic PARP in both non-transformed
cultures (Fig. 3A, lane 2) and cultures undergoing Ras-induced
cellular transformation (lane 6). The pre-treatment of cultures
with Ac-Asp-Glu-Val-Asp-CHO resulted in decreased produc-
tion of proteolytic PARP (Fig. 3A) and in reduced cell death
(Fig. 3B) in both non-transformed (lane and column 4) and
Ras-transformed (lane and column 8) cells induced by
FR901228. These results conﬁrmed the involvement of cas-
pase-3 activity in FR901228-induced apoptosis. Our previous
results suggested that the highly elevated procaspase-3 protein
content in Ras-transformed cells may facilitate the selective
apoptosis induced by FR901228 via eﬃcient conversion of pro-
caspase-3 to active caspase-3 [10]. In this communication, either
blockage of the ERK pathway which results in profound reduc-
tion of procaspase-3 content in Ras-transformed cells [10] orFig. 3. FR901228-induced cell death modulated by the caspase-3
pathway. Cultures of 10T1/2-TR-H-ras cells were pretreated with 200
lM caspase-3 inhibitor (C3-I) Ac-Asp-Glu-Val-Asp-CHO for 3 h.
Then, cultures were incubated with 100 ng/ml tetracycline (Tet) to
induce ectopic expression of H-Ras in the absence () and presence (+)
of 1 nM FR901228 (FR) for 36 h. (A) Cell lysates were analyzed by
Western immunoblotting to detect levels of cleaved fragment of PARP
indicated by an arrow. (B) Quantiﬁcation of cell death in these cultures
was determined. Relative cell death was normalized by the value
determined in untreated cells which was set as 1. Each value represents
a mean of triplicates and error bars represent standard deviation.
Statistical signiﬁcance was analyzed by Students t test. a indicates that
P < 0.05 versus FR (column 2). b indicates that P < 0.05 versus FR/Tet
(column 6).inhibition of caspase-3 directly reduced FR901228-induced
apoptosis of Ras-transformed cells. Accordingly, the ERK
pathway may contribute to the pro-apoptotic role of oncogenic
H-Ras to FR901228 treatment via the procaspase-3 to caspase-
3 pathway. Blockage of the ERK pathway in Ras-transformed
cells reduced the extents of cell death to a level similar to the cell
death induced in non-transformed cultures by the FR901228
when the ERK pathway was also blocked (Fig. 2C-2). Possibly,
blockage of the ERK pathway in Ras-transformed cells results
in not only abrogating its pro-apoptotic potential through
reduction of procaspase-3, but also abolishing its anti-apoptotic
activity to protect cells from FR901228-induced cell death.
However, suppression of caspase-3 activity is not suﬃcient to
completely inhibit FR901228-induced apoptosis. Apparently,
other pathways involved in the pro-apoptotic activity of onco-
genic Ras to increase the cell susceptibility to FR901228 need to
be identiﬁed.Acknowledgments: We are grateful to Dr. R. Moore for critical com-
ments on the manuscript. This research was supported mainly by
grants to H.-C.R. Wang from The National Institutes of Health
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